CN104072431B - The compound of the Phenyltriazole schiff bases structure that alkoxyl group replaces and purposes - Google Patents
The compound of the Phenyltriazole schiff bases structure that alkoxyl group replaces and purposes Download PDFInfo
- Publication number
- CN104072431B CN104072431B CN201410352029.6A CN201410352029A CN104072431B CN 104072431 B CN104072431 B CN 104072431B CN 201410352029 A CN201410352029 A CN 201410352029A CN 104072431 B CN104072431 B CN 104072431B
- Authority
- CN
- China
- Prior art keywords
- compound
- phenyltriazole
- purposes
- schiff bases
- par
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims description 27
- 125000003545 alkoxy group Chemical group 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 230000002785 anti-thrombosis Effects 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 abstract description 9
- 229940098892 Protease-activated receptor-1 antagonist Drugs 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 4
- 239000002262 Schiff base Substances 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- -1 triazole schiff base compounds Chemical class 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 8
- 206010003178 Arterial thrombosis Diseases 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102100037136 Proteinase-activated receptor 1 Human genes 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 101710121440 Proteinase-activated receptor 1 Proteins 0.000 description 4
- 102000003790 Thrombin receptors Human genes 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010070519 PAR-1 Receptor Proteins 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- FHZSIZRTNHGLSX-FLMSMKGQSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 FHZSIZRTNHGLSX-FLMSMKGQSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108090000166 Thrombin receptors Proteins 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108010093640 thrombin receptor peptide SFLLRNP Proteins 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- YUAQBWPEMDOFCS-JEPNHJGPSA-N CC(C)(C)c(cc(cc1N2CCOCC2)C(CSc2nnc(-c3cc(Cl)ccc3)[n]2/N=C/C(CC=C2)C=C2OC)=O)c1OC Chemical compound CC(C)(C)c(cc(cc1N2CCOCC2)C(CSc2nnc(-c3cc(Cl)ccc3)[n]2/N=C/C(CC=C2)C=C2OC)=O)c1OC YUAQBWPEMDOFCS-JEPNHJGPSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 1
- 102000032626 PAR-1 Receptor Human genes 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 238000007395 thrombosis prophylaxis Methods 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940019333 vitamin k antagonists Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to the pharmaceutical field relevant to thrombotic diseases.The invention belongs to triazole schiff base compounds and the derivative thereof of the brand-new skeleton of a class, the PAR-1 antagonist of Phenyltriazole schiff bases structure replaced in particular to a class end alkoxy group, its preparation method and containing their pharmaceutical composition and their purposes in preparation treatment thrombotic diseases medicine.
Description
Technical Field
The invention relates to the field of medicines related to thrombotic diseases. The invention belongs to triazole Schiff base compounds with a brand-new framework and derivatives thereof, and particularly relates to PAR-1 antagonists with a terminal alkoxy substituted phenyl triazole Schiff base structure, a preparation method thereof and a pharmaceutical composition containing the same, wherein the PAR-1 antagonists have a therapeutic effect on thrombotic diseases.
Background
The protease activated receptor 1 (ProteaActivatedAcceptor-1, PAR-1) is a new target of the recently discovered anti-platelet antithrombotic drugs. The protease activated receptor 1 is called thrombin receptor, and after thrombin is activated by the coagulation chain, the thrombin acts on platelets through a PAR-1 receptor to activate the platelets, so that the platelets are aggregated to cause thrombosis and coagulation. The thrombus caused by PAR-1 is rich in platelet components and is the main cause of arterial thrombosis. PAR-1 antagonists block the activation of platelets by thrombin and thus block arterial thrombosis and can be used for the treatment of acute coronary artery disease (AcutesoronarySyndrome). Several PAR-1 inhibitors have been in clinical study (Chackalamannil S., Thrombin Receptor (ProteaActivatedReceptor-1) AntagonisstsA ScientticoagentswithStrongAntiemplateEffects,J.Med.Chem.,2006,49(18),5389-5403)。
the traditional medicines for preventing and treating thrombotic diseases are divided into three categories. The first class is the anticoagulant class, which is divided into direct thrombin inhibitors and indirect thrombin inhibitors, the drugs inhibit thrombosis by acting on different links of the coagulation linkage, and have the effect of inhibiting various thrombosis, such as vitamin K antagonists, Xa factor inhibitors and the like; the second category is anti-platelet, such as COX-1 inhibitor, ADP receptor antagonist and the like, and the drugs are mainly used for preventing and treating arterial thrombosis; the third type is a fibrinolytic agent, which is mainly used to dissolve fibrin formed in blood.
Most antiplatelet drugs are traditional arterial thrombosis prevention drugs, such as clopidogrel, aspirin and the like. The disadvantage of these drugs is the relatively high risk of bleeding. PAR-1 antagonists, which are newly discovered antiplatelet antithrombotic agents, have smaller bleeding risks, so the compounds can be used as promising drugs for treating arterial thrombosis.
The invention discloses a PAR-1 antagonist with a terminal alkoxy substituted phenyl triazole Schiff base structure, which can be used for preparing medicines for resisting arterial thrombosis diseases.
Disclosure of Invention
It is an object of the present invention to provide a compound of formula (I) having good antithrombotic activityIAnd pharmaceutically acceptable salts thereof.
It is another object of the present invention to provide a process for the preparation of a compound of the formulaIAnd pharmaceutically acceptable salts thereof.
It is a further object of the present invention to provide a composition comprisingIThe compound and the pharmaceutically acceptable salt thereof as effective components, and one or more pharmaceutically acceptable carriers, excipients or diluents, and application thereof in treating arterial thrombosis.
The present disclosure will now be described in detail for the purpose of the invention.
The compounds of the present invention having the general formula I have the following structural formula:
（I）。
wherein,
R1selected from: H. a halogen substituent;
R2selected from: C1-C5 alkyl and C3-C5 cycloalkyl.
Compounds of formula I and pharmaceutically acceptable salts thereof, are preferably selected from:
wherein,
R1selected from: H. f, Cl and Br substituents;
R2selected from: C1-C3 alkyl.
Preferably the following has the general formulaIThe compound of (a) to (b),
。
further, the following compounds having the general formula (III)IThe compound of (a) to (b),
、。
the general formula of the inventionIThe compound was synthesized by the following steps:
。
compound (I)IIAnd compoundsIIIReacting under the catalysis of acid or alkali to obtain Schiff baseIV；IVAndVreacting in the presence of a base to obtain a compoundI。
The invention is of the formulaIPharmaceutically acceptable salts of the compounds include, but are not limited to, salts with various inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, and the like, and also salts with various organic acids such as acetic acid, succinic acid, maleic acid, malic acid, and various amino acids, and the like.
The general formula of the inventionIThe compound has PAR-1 antagonistic effect, and can be used as effective component for preparing antithrombotic therapeutic medicine. The general formula of the inventionIThe activity of the compounds was verified by in vitro models.
The general formula of the inventionIThe compounds are effective over a relatively wide dosage range. For example, the daily dosage may be in the range of about 1mg to 500mg per person, divided into one or more administrations. Practical administration of the inventionIThe dosage of the compound can be determined by a physician in the light of the relevant circumstances. These include: the physical state of the subject, the route of administration, the age, body weight, individual response to the drug, severity of the symptoms, and the like.
Detailed Description
The present invention will be further described with reference to the following examples. It should be noted that the following examples are only for illustration and are not intended to limit the present invention. Variations of the teachings of the present invention may be made by those skilled in the art without departing from the scope of the claims of the present application.
Example 1
Reaction raw materials: self-made and conventional method.
1.36g (10mmol) of the CompoundII-1And 2.10g (10mmol) of the compoundIII-1Dissolved in 20mL of glacial acetic acid and refluxed at elevated temperature overnight. After the reaction mixture was slightly cooled, it was poured into 200mL of ice water, stirred, suction filtered to collect the solid, recrystallized from absolute ethanol, and vacuum dried at room temperature to give the productIV-1White crystals. The MS is a Mobile Station (MS),m/z=329([M+H]+)。
1.65g (5mmol) of the CompoundIV-11.85g (5mmol) of the compoundVAnd 2.07g (15mmol) of solid potassium carbonate in 15mL acetonitrile were stirred overnight, followed by heating and refluxing for 3 hours. Pouring the reaction mixture into 200mL of ice water after slightly cooling, stirring, adjusting the pH to =4 with concentrated hydrochloric acid, extracting with 50mL of x 3 dichloromethane, combining the organic phases, washing with brine, drying over anhydrous sodium sulfate, evaporating the solvent on a rotary evaporator, and purifying the obtained residue by column chromatography to obtain a pure productI-1The white solid, MS,m/z=635([M+NH4]+)。
examples 2 to 8
With reference to the procedure of example 1, a compound having the general formulaIThe following compounds of (a):
。
example 9 in vitro platelet aggregation inhibition assay
Pharmacological testing of the substances was performed in 96-well plates, with TRAP (thrombin receptor activating peptide) -induced platelet aggregation. The syringe was primed with a 3.13% sodium citrate solution and then 20mL of blood was drawn from healthy volunteers at 1500gPlatelet Rich Plasma (PRP) was separated by centrifugation for 20 minutes and treated with 1. mu.L of LPGE1 solution (500. mu.g/mL of ethanol solution)/mLPRP. After 5 min incubation at room temperature, it was centrifuged at 1200g for 20 min to remove leukocytes. PRP without leukocytes was transferred in 5mL portions to 15mL PP tubes and pelleted by centrifugation at 3600 g. Then, the upper plasma was decanted, and the platelet pellet from 5 mlprep was resuspended in 1mLTyrode (120mMNaCl, 2.6mMKCl, 12mMNaHCO3, 0.39mMNaH2PO4, 10 mhepes, 0.35% BSA, 5.5mM glucose, pH =7.4) and adjusted to a platelet count of 3 × 105/μ L with Tyrode. 13mL of this cell suspension are treated with 866. mu.l of a 10mM CaCl2 solution and pipetted into a 96-well plate in an amount of 120. mu.l per well, into whose wells 15. mu.l of the test substance have been added beforehand. Incubate in the dark at room temperature for 30 min, add 15 μ LTRAP solution (70-100 μ M) as agonist, shake at 37 ℃ for 20 min in SpectraMax, record kinetics at 650nm, calculate the area under the curve for negative control (tyrode/DMSO) and positive control (15 μ L agonist/DMSO), and set the difference to 100%. Compounds to be tested were pipetted as serial dilutions and assayed in duplicate, the AUC for each substance concentration was also determined and% AUC inhibition compared to control was calculated. The IC50 values were calculated from the% inhibition by means of non-linear regression analysis according to the 4-parameter equation. The following table gives the results:
as can be seen from the above table, the compounds of the present invention showed significant inhibition in the platelet aggregation assay.
Claims (5)
1. A compound with a structure shown in a general formula I and pharmaceutically acceptable salts thereof,
wherein,
R1selected from: H. a halogen substituent;
R2selected from: C1-C5 alkyl.
2. A compound of formula I as defined in claim 1,
wherein,
R1selected from: H. f, Cl and Br substituents;
R2selected from: C1-C3 alkyl.
3. A compound of the general formula I as defined in claim 2, selected from the group consisting of,
4. a compound of the general formula I as defined in claim 3, selected from the group consisting of,
5. use of a compound of general formula I as defined in claims 1 to 4 and pharmaceutically acceptable salts thereof for the manufacture of a medicament for the treatment of antithrombotic diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410352029.6A CN104072431B (en) | 2014-07-23 | 2014-07-23 | The compound of the Phenyltriazole schiff bases structure that alkoxyl group replaces and purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410352029.6A CN104072431B (en) | 2014-07-23 | 2014-07-23 | The compound of the Phenyltriazole schiff bases structure that alkoxyl group replaces and purposes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104072431A CN104072431A (en) | 2014-10-01 |
| CN104072431B true CN104072431B (en) | 2015-11-18 |
Family
ID=51594079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410352029.6A Expired - Fee Related CN104072431B (en) | 2014-07-23 | 2014-07-23 | The compound of the Phenyltriazole schiff bases structure that alkoxyl group replaces and purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104072431B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104529928A (en) * | 2015-01-13 | 2015-04-22 | 佛山市赛维斯医药科技有限公司 | One category of oxadiazole sulfoxide compounds, and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102442965A (en) * | 2010-09-30 | 2012-05-09 | 天津药物研究院 | PAR-1 (protease-activated receptor-1) antagonists for treating thrombotic diseases, as well as preparation and application thereof |
| CN103613553A (en) * | 2013-12-09 | 2014-03-05 | 兴义民族师范学院 | S-triazole Schiff base bisamide derivative as well as preparation method and usage thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2239806T3 (en) * | 1997-06-19 | 2005-10-01 | Bristol-Myers Squibb Pharma Company | XA FACTOR INHIBITORS WITH A P1 NEUTRAL SPECIFICITY GROUP. |
-
2014
- 2014-07-23 CN CN201410352029.6A patent/CN104072431B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102442965A (en) * | 2010-09-30 | 2012-05-09 | 天津药物研究院 | PAR-1 (protease-activated receptor-1) antagonists for treating thrombotic diseases, as well as preparation and application thereof |
| CN103613553A (en) * | 2013-12-09 | 2014-03-05 | 兴义民族师范学院 | S-triazole Schiff base bisamide derivative as well as preparation method and usage thereof |
Non-Patent Citations (2)
| Title |
|---|
| 3-甲基-4-氨基-5-乙氧羰基甲硫基三唑席夫碱的合成及生物活性;杨清翠等;《化学通报》;20131231;第76卷(第8期);第758-761页 * |
| Thrombin Receptor (Protease Activated Receptor-1) Antagonists as Potent Antithrombotic Agents with Strong Antiplatelet Effects;Samuel Chackalamannil;《Journal of Medicinal Chemistry》;20060907;第49卷(第18期);第5389-5403页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104072431A (en) | 2014-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104072434B (en) | Between position replace tetrazole acetophenone compound, Preparation Method And The Use | |
| CN104098520B (en) | Phenyltriazole schiff base compounds, Preparation Method And The Use | |
| CN104072436B (en) | The tetrazole acetophenone compound of para-orientation, Preparation Method And The Use | |
| CA3171258A1 (en) | Mdm2 degraders and uses thereof | |
| CN104072438B (en) | Dialkoxy is for tetrazole acetophenone compound, Preparation Method And The Use | |
| CN104529927B (en) | One class is containing oxadiazoles sulfoxide compound, the Preparation Method And The Use of halogeno-benzene | |
| CN104072437B (en) | Disubstituted tetrazole acetophenone compound, Preparation Method And The Use | |
| CN104072439B (en) | The tetrazole acetophenone compound of halogen substiuted, Preparation Method And The Use | |
| CN104072431B (en) | The compound of the Phenyltriazole schiff bases structure that alkoxyl group replaces and purposes | |
| CN104072432B (en) | Containing compound, the Preparation Method And The Use of phenyl substituted triazole schiff bases class formation | |
| AU2011345414B2 (en) | Substituted methyl amines, serotonin 5-HT6 receptor antagonists, methods for the production and use thereof | |
| CN104086493B (en) | Compound of the Phenyltriazole schiff bases structure that end replaces and uses thereof | |
| CN104086498B (en) | Compound, the Preparation Method And The Use of the triazole schiff bases class formation that end replaces | |
| CN104086495B (en) | End disubstituted triazole schiff bases structural compounds, Preparation Method And The Use | |
| CN104086494B (en) | End disubstituted methyl-triazole schiff bases structural compounds, Preparation Method And The Use | |
| CN104086497B (en) | Triazole schiff base compounds, Preparation Method And The Use | |
| CN104140398B (en) | Compound, the Preparation Method And The Use of methyl-triazole schiff bases class formation | |
| CN105008366A (en) | Pyrrolopyridazines as potassium ion channel inhibitors | |
| CN104072435B (en) | The tetrazole acetophenone compound that two alkyl replaces and purposes | |
| CN104086502B (en) | Halo tetrazole acetophenone compound, Preparation Method And The Use | |
| CN105026399A (en) | Pyrrolotriazines as potassium ion channel inhibitors | |
| EP2054412B1 (en) | Imino-imidazo-pyridine derivatives having antithrombotic activity | |
| CN104529931B (en) | One class is containing oxadiazoles sulfoxide compound, the Preparation Method And The Use of alcoxyl para-orientation benzene | |
| CN104529929B (en) | Containing oxadiazoles sulfoxide compound, the Preparation Method And The Use of alcoxyl substituted benzene | |
| CN104529930B (en) | One class nitrile group-containing Ben oxadiazole sulfoxide compound, Preparation Method And The Use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170731 Address after: 510640 Guangdong City, Tianhe District Province, No. five, road, public education building, unit 371-1, unit 2401 Patentee after: Guangdong Gaohang Intellectual Property Operation Co., Ltd. Address before: 528000 Guangdong, Foshan District, Pu Lan Road, the first floor of the first floor, No. 5, Chancheng Patentee before: Zhang Yuanqiang |
|
| CB03 | Change of inventor or designer information |
Inventor after: Lu Jun Inventor before: Zhang Yuanqiang |
|
| CB03 | Change of inventor or designer information | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170823 Address after: 075000, No. 6, north gate, South Station, Qiaodong District, Hebei, Zhangjiakou Patentee after: Lu Jun Address before: 510640 Guangdong City, Tianhe District Province, No. five, road, public education building, unit 371-1, unit 2401 Patentee before: Guangdong Gaohang Intellectual Property Operation Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151118 Termination date: 20180723 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |